Protein modified by researchers may reduce heart attack damage

Following heart attack, heart cells are stressed due to lack of oxygen. When SuperFAK (in green) is expressed in the heart, it is further activated and protects heart cells from oxidative stress (in red). Credit: Joan Taylor, Ph.D

Scientists modified a protein in the heart which dramatically reduced cell damage after heart attacks, according to new research published the American Heart Association journal Arteriosclerosis, Thrombosis and Vascular Biology.

The modified protein reduced cell damage by 50 percent in mice without causing harmful inflammation, the researchers found. Those results came during research looking at ways to prevent induced by heart attack.

The protein is called focal adhesion kinase, or FAK. It organizes cell structure by activating various processes that help the cells stay alive.

"FAK is important for basic processes in all cells, and it appears to be important for , growth and migration in a number of cell types, but is especially critical in the heart," said Joan Taylor, Ph.D., who has been studying FAK in mice at the Department of Pathology and Lab Medicine at the University of North Carolina.

FAK can create problems, too. In earlier research, the scientists found that it was activated in the heart after a heart attack, and spurred a series of events that could lead to inflammation and permanent .

"Inflammation is important to get rid of , but if that goes uncontrolled, the inflammation kills viable heart cells," Taylor said.

That's when the researchers began working to build a better FAK, one that would initiate the survival response without causing excessive inflammation. Taylor's former University of North Carolina colleague, Mike Schaller, Ph.D., created what they called SuperFAK, which exhibited increased but controlled activity.

In mice with the new SuperFAK gene, researchers saw a massive activation of FAK after heart attack, and not as many died compared to unaltered mice. Three days after the induced heart attack, the SuperFAK mice had about 50 percent less heart injury than the unaltered mice. This benefit was maintained for eight weeks.

"We think because the modified FAK resolved its activity in 24 hours, it limited the inflammation response, and only activated beneficial signals," Taylor said.

FAK also plays a role in the development of a number of cancers and has been linked to tumor growth and metastases. Some chemotherapies hamper FAK, leaving the heart vulnerable. Progressive cardiac damage is a common adverse effect of several chemotherapeutic treatments. In the future, they hope to develop drugs to target FAK to protect the heart during chemotherapy or following a heart attack.

add to favorites email to friend print save as pdf

Related Stories

When cancer cells can't let go

Apr 13, 2009

Like a climber scaling a rock face, a migrating cancer cell has to keep a tight grip on the surface but also let go at the right moment to move ahead. Chan et al. reveal that the focal adhesion kinase (FAK) ...

Gene predicts heart attack response and cardiac damage

Jan 30, 2008

A protein has been found that influences the response of the heart to a lack of oxygen and blood flow, such as occurs during a heart attack, a team of Yale School of Medicine researchers report today in Nature.

Cardiac cells might help fix heart attack damage

Jun 08, 2011

(AP) -- Scientists say they've found cells in the hearts of mice that can make new muscle after a heart attack, raising hopes that doctors can one day help the human heart repair itself.

Recommended for you

A global view on the prevention of cardiovascular disease

21 hours ago

The United Nations and the World Health Organization pledged in 2011 to reduce premature mortality from non-communicable diseases - most notably cardiovascular diseases - by 25% by the year 2025. It's an ambitious target, ...

Stroke healthcare inequalities remain in the UK

Apr 15, 2014

The quality of healthcare provided after a stroke remains uneven in the UK, according to a new study led by King's College London. Despite improvements in equal access to healthcare since 2001, patients from ...

FDA approves expanded indication for CRT devices

Apr 15, 2014

(HealthDay)—The U.S. Food and Drug Administration has approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers (CRT-P) and eight cardiac resynchronization ...

User comments